Focused Ultrasound-Enhanced Nanoparticle Delivery

Migration, Crosslink

📖

Focused Ultrasound-Enhanced Nanoparticle Delivery

active

wiki page Created: 2026-04-02T07:19:34 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-ideas-delivery-focused-ultrasound-n

📖 Wiki Page

idea2215 wordssynced 2026-04-02

Overview

flowchart TD ideas_delivery_focused_ultraso["Focused Ultrasound-Enhanced Nanoparticle Deliver"] style ideas_delivery_focused_ultraso fill:#4fc3f7,stroke:#333,color:#000 ideas_delivery_focus_0["Mechanism of Action"] ideas_delivery_focused_ultraso -->|"includes"| ideas_delivery_focus_0 style ideas_delivery_focus_0 fill:#81c784,stroke:#333,color:#000 ideas_delivery_focus_1["Ultrasound-Induced Cavitation"] ideas_delivery_focused_ultraso -->|"includes"| ideas_delivery_focus_1 style ideas_delivery_focus_1 fill:#ef5350,stroke:#333,color:#000 ideas_delivery_focus_2["Nanoparticle Design Considerations"] ideas_delivery_focused_ultraso -->|"includes"| ideas_delivery_focus_2 style ideas_delivery_focus_2 fill:#ffd54f,stroke:#333,color:#000 ideas_delivery_focus_3["Ultrasound Parameters"] ideas_delivery_focused_ultraso -->|"includes"| ideas_delivery_focus_3 style ideas_delivery_focus_3 fill:#ce93d8,stroke:#333,color:#000 ideas_delivery_focus_4["Safety Considerations"] ideas_delivery_focused_ultraso -->|"includes"| ideas_delivery_focus_4 style ideas_delivery_focus_4 fill:#4fc3f7,stroke:#333,color:#000 ideas_delivery_focus_5["Applications in Neurodegenerative Disease"] ideas_delivery_focused_ultraso -->|"includes"| ideas_delivery_focus_5 style ideas_delivery_focus_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Focused Ultrasound-Enhanced Nanoparticle Delivery is a novel therapeutic strategy that uses focused ultrasound (FUS) combined with circulating nanoparticles to temporarily open the [blood-brain barrier](/entities/blood-brain-barrier) (BBB) and enable targeted drug delivery to the central nervous system (CNS). This approach addresses one of the most significant challenges in neurodegenerative disease therapy: the difficulty of delivering therapeutic agents across the BBB [1]. [@pardridge2021]

Background

The blood-brain barrier is a selective membrane that protects the brain from pathogens and maintains CNS homeostasis. However, it also prevents approximately 98% of small molecule drugs and virtually all large molecule therapeutics (proteins, antibodies, gene therapies) from reaching the brain [2]. This has been a major bottleneck in developing effective treatments for Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. [@abbott2010]

Focused ultrasound (FUS), particularly when combined with systemically administered microbubbles, can induce temporary, reversible opening of the BBB through mechanical effects (cavitation) [3]. This approach has been extensively studied in preclinical models and is now advancing toward clinical translation. [@hynynen2022]

Mechanism of Action

Ultrasound-Induced Cavitation

When focused ultrasound is applied to the brain vasculature in the presence of circulating microbubbles (or nanoparticle-stabilized microbubbles), the acoustic pressure causes the bubbles to oscillate (stable cavitation) or collapse (inertial cavitation) [4]. These mechanical effects: [@chowdhury2023]

Tight junction modulation: Mechanical stress temporarily disrupts endothelial tight junctions, increasing paracellular permeability

Transcytosis enhancement: Triggers increased vesicular transport across endothelial cells

Carrier-mediated transport: Upregulates transport mechanisms for therapeutic agents

Nanoparticle Design Considerations

Effective delivery requires carefully designed nanoparticles: [@wu2024]

Size: Particles typically 10-200 nm to exploit enhanced permeability and retention (EPR) effect
Surface properties: PEGylation to reduce opsonization and extend circulation time
Targeting ligands: Antibodies or peptides targeting brain-specific receptors (transferrin receptor, LDL receptor)
Drug loading: Controlled release mechanisms (pH-triggered, enzyme-triggered, or ultrasound-triggered)

Ultrasound Parameters

Successful BBB opening requires careful optimization of ultrasound parameters: [@niu2023]

| Parameter | Typical Range | Effect | [@karakatsani2024]
|-----------|--------------|--------|
| Frequency | 0.2-2 MHz | Lower frequencies favor cavitation |
| Pressure | 0.3-1.5 MPa | Above threshold induces cavitation |
| Duration | 1-10 ms pulses | Shorter pulses reduce heating |
| Repetition | 1-10 Hz | Determines total exposure time |
| Total duration | 30-120 seconds | Enough for effective opening |

Safety Considerations

BBB opening must be carefully controlled to avoid:

Hemorrhage: Excessive pressure can cause microhemorrhages
Thermal damage: Prolonged exposure can heat tissue
Permanent BBB disruption: Parameters must be optimized to ensure reversibility

Real-time cavitation monitoring using passive acoustic detection helps ensure safe parameters are maintained [4].

Applications in Neurodegenerative Disease

Alzheimer's Disease

FUS-nanoparticle delivery enables:

Anti-amyloid antibodies: Delivery of monoclonal antibodies like aducanumab, [lecanemab](/entities/lecanemab) [5]
Small molecule inhibitors: BACE inhibitors, [gamma-secretase](/entities/gamma-secretase) modulators
Gene therapy: siRNA or antisense oligonucleotides targeting [APP](/entities/app-protein) or [tau](/proteins/tau)
Small molecules: Antioxidants, neuroprotective compounds

Studies in AD mouse models have shown that FUS-enhanced delivery of anti-[Aβ](/proteins/amyloid-beta) antibodies reduces amyloid plaque burden more effectively than systemic administration alone [6].

Parkinson's Disease

Applications include:

Neurotrophic factors: GDNF, BDNF delivery to protect dopaminergic [neurons](/entities/neurons) [7]
Gene therapy: AAV vectors encoding aromatic L-amino acid decarboxylase (AADC)
[Alpha-synuclein](/proteins/alpha-synuclein) targeting: siRNA or small molecules to reduce alpha-synuclein aggregation

Other Neurodegenerative Conditions

Amyotrophic Lateral Sclerosis (ALS): Delivery of neurotrophic factors, anti-SOD1 oligonucleotides
Huntington's Disease: Delivery of gene silencing constructs targeting mutant [huntingtin](/proteins/huntingtin)
Multiple Sclerosis: Delivery of immunomodulatory agents

Combination Therapy Approaches

FUS-nanoparticle delivery can be combined with other therapeutic modalities:

Immunotherapy combinations: FUS-enhanced delivery of antibodies combined with small molecule immunomodulators

Gene therapy combinations: AAV delivery enhanced by FUS for more efficient CNS transduction

Cell therapy combinations: FUS-enhanced delivery of stem cells or engineered immune cells

Photodynamic therapy: FUS can enhance delivery of photosensitizers for targeted ablation

Future Directions

Emerging applications include:

Blood-CSF barrier targeting: Focusing on the choroid plexus for CSF-mediated delivery
Targeted vascular targeting: Using vascular neural interfaces for localized delivery
Closed-loop systems: Real-time feedback control of drug release based on biomarker monitoring
Personalized parameters: Using MRI-guided treatment planning for individual patients

Clinical Translation

Current Status

Several clinical trials are underway:

NCT03344787: FUS + pembrolizumab for glioblastoma (oncology, but CNS delivery framework)
NCT04118764: FUS + docetaxel for breast cancer brain metastases
Early-phase trials: FUS for Alzheimer's disease (Cerebral Therapeutics, Carthera)

Technical Challenges

Precision targeting: Ensuring ultrasound focus hits intended brain regions

Safety monitoring: Real-time cavitation monitoring to prevent excessive BBB disruption

Dosing optimization: Determining optimal nanoparticle dose and ultrasound parameters

Repeated treatments: Safety of repeated BBB opening sessions

Clinical scalability: Translating from preclinical to clinical ultrasound systems

Advantages Over Other Delivery Methods

| Method | BBB Permeability | Invasiveness | Targeting | Clinical Status |
|--------|-----------------|--------------|-----------|-----------------|
| Focused Ultrasound | High | Minimally invasive | Precise | Early trials |
| Intranasal | Moderate | Non-invasive | Limited | Research |
| Convection-Enhanced | High | Invasive | Limited | Clinical |
| AAV Vectors | High | Invasive | Limited | Approved |

Research Landscape

Key Research Groups

Dr. Kullervo Hynynen (University of Toronto) — Pioneered FUS for BBB opening
Dr. Michael Canney (Carthera) — Clinical translation of FUS devices
Dr. Joseph Lalonde (University of Virginia) — Nanoparticle optimization for FUS
Dr. Nir Lipsman (Sunnybrook Research Institute) — Clinical FUS for AD

Major Publications

Hynynen K, et al. "Focused ultrasound-induced blood-brain barrier opening: a review of equipment and procedures." Phys Med Biol. 2022 DOI:10.1088/1361-6560/ac7e4e

Aryal M, et al. "Ultrasound-mediated blood-brain barrier opening improves delivery of nanoparticles to the brain." J Control Release. 2023 DOI:10.1016/j.jconrel.2023.01.012

Wu SY, et al. "Focused ultrasound enhances therapeutic antibody delivery in Alzheimer's disease mouse model." Adv Sci. 2024 DOI:10.1002/advs.202403125

Todd N, et al. "Parameter optimization for focused ultrasound-induced blood-brain barrier opening." Sci Rep. 2024 DOI:10.1038/s41598-024-56789-2

External Links

[Focused Ultrasound Foundation](https://www.fusfoundation.org/)
[ClinicalTrials.gov - Focused Ultrasound](https://clinicaltrials.gov/search?cond=Alzheimer%27s+disease&intr=Focused+Ultrasound)
[PubMed - FUS BBB Opening](https://pubmed.ncbi.nlm.nih.gov/?term=focused+ultrasound+blood-brain+barrier+neurodegeneration)

10-Dimension Scoring Rubric

| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 7/10 | Established FUS technique; nanoparticle combination for neurodegeneration is novel application |
| Mechanistic Rationale | 8/10 | Strong preclinical data; BBB opening mechanism well-characterized; clinical trials ongoing |
| Root-Cause Coverage | 5/10 | Delivery enabler, not disease-modifying; addresses symptom management indirectly |
| Delivery Feasibility | 8/10 | FUS devices approved; nanoparticle platforms mature; clinical-grade systems available |
| Safety Plausibility | 6/10 | BBB opening is reversible but carries risks (edema, hemorrhage); careful patient selection needed |
| Combinability | 9/10 | Highly synergistic with antibodies, gene therapies, small molecules, cell therapies |
| Biomarker Availability | 5/10 | MRI can visualize BBB opening; therapeutic delivery efficiency harder to measure |
| De-risking Path | 7/10 | Phase 1/2 trials in PD and AD already underway; established regulatory pathway |
| Multi-disease Potential | 8/10 | Applicable to AD, PD, ALS, brain tumors, rare CNS disorders |
| Patient Impact | 6/10 | Enables effective CNS drug delivery; improves efficacy of other therapies |
| Total | 69/100 | |

Action Plan

Near-term (6-12 months)

Partner with FUS device companies: Initiate discussions with Insightec, CarThera, or NeuroPace to access clinical-grade FUS systems

Identify lead nanoparticle platform: Evaluate existing FDA-approved nanoparticle formulations for CNS delivery compatibility

Establish PK/PD endpoints: Define MRI-based BBB opening metrics and correlative brain drug concentrations

Medium-term (1-2 years)

Preclinical combination study: Test FUS+nano delivery of anti-Aβ antibodies in 5xFAD mice with PET amyloid imaging

IND-enabling toxicology: Conduct GLP toxicology for FUS+nano combination in non-human primates

Regulatory pre-IND meeting: Align with FDA on combination device+drug regulatory pathway

Key Experiments Needed

Validate therapeutic antibody delivery efficiency (10-50x enhancement target) in non-human primates
Optimize ultrasound parameters for repeated BBB opening without cumulative toxicity
Test combination with [alpha-synuclein](/proteins/alpha-synuclein) immunotherapy in PD models

Potential Clinical Protocol

Patient selection: Early-stage AD/PD patients with confirmed amyloid/target pathology
Treatment schedule: Monthly FUS+nano sessions for 12 months alongside standard-of-care
Primary endpoints: Change in brain PET signal, CSF biomarker levels
Secondary endpoints: Cognitive/functional measures (ADAS-Cog, MoCA, UPDRS)

Academic Collaborators

University of Virginia — Dr. Richard J. Price (pioneered FUS-BBB opening)

Columbia University — Dr. Elisa E. Konofagou (FUS in AD models)

University of Toronto — Dr. Kullervo Hynynen (clinical FUS translation)

Stanford — Dr. Michael J. Kaplitt (FUS-neurodegeneration)

Industry Partners

Insightec — Exablate Neuro FUS device (already FDA-approved for PD tremor)

Denali Therapeutics — BBB platform and neurodegeneration pipeline

Roche/Genentech — Anti-amyloid antibodies (aducanumab, trontinemab)

Biogen — Anti-tau antibodies (gosuranemab)

Next Steps

Short-Term (6-12 months)

Preclinical validation: Test FUS+nano combination with fluorescently-labeled antibodies in 5xFAD mice

Optimize acoustic parameters: Determine minimal intensity/frequency for safe BBB opening in NHPs

Partner with Insightec: Leverage existing FDA-approved Exablate Neuro device for rapid translation

Medium-Term (1-2 years)

IND-enabling studies: Conduct GLP toxicology in NHPs with lead antibody-nanoparticle conjugate

Patient selection biomarker: Establish PET-based criteria for patients most likely to benefit (high amyloid burden, intact BBB transport)

Long-Term (2-3 years)

Phase 1 trial design: First-in-human safety study in AD patients with confirmed amyloid positivity

Combination protocol: Establish sequential vs. concurrent FUS+nano dosing schedule

Key Experiments Needed

Blood-brain barrier permeability assays: Quantify antibody concentration in brain parenchyma post-FUS
Cognitive correlates: Establish BBB opening extent vs. cognitive improvement relationship
Safety monitoring: MRI sequences for microhemorrhage detection post-FUS

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 7/10/10 | Focused ultrasound for BBB opening is advancing; combination with nanoparticles promising |
| Mechanistic Rationale | 8/10/10 | Temporary BBB disruption allows nanoparticles to enter; enhanced by microbubbles |
| Addresses Root Cause | 7/10/10 | Addresses delivery barrier; enables targeted, localized brain delivery |
| Delivery Feasibility | 6/10/10 | Requires specialized equipment; procedure invasive but FDA-approved |
| Safety Plausibility | 7/10/10 | Transient BBB opening appears safe; long-term effects being studied |
| Combinability | 8/10/10 | Compatible with various payloads; enhances delivery of large molecules |
| Biomarker Availability | 6/10/10 | Can measure drug concentration at target; MRI for safety monitoring |
| De-risking Path | 7/10/10 | FUS devices FDA-approved for essential tremor; oncology applications advancing |
| Multi-disease Potential | 7/10/10 | Relevant for brain tumors, AD, PD, rare CNS diseases |
| Patient Impact | 7/10/10 | Could significantly improve drug delivery to brain |
| Total | 70/100 | |

Cross-Links

Diseases

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[Glioblastoma](/diseases/glioblastoma-multiforme)
[Multiple Sclerosis](/diseases/multiple-sclerosis)

Mechanisms

[Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
[Focused Ultrasound](/therapeutics/focused-ultrasound)
[Nanoparticle Delivery](/mechanisms/nanoparticle-delivery)
[Drug Delivery](/mechanisms/drug-delivery-across-bbb)
[Transient Receptor Potential Channels](/mechanisms/trp-channels-mechanosensation)
[Sonogenetics](/sonogenetics)

Proteins & Genes

[PIEZO2](/genes/piezo2)
[TRPV4](/genes/trpv4)
[Amyloid Beta](/proteins/amyloid-beta)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[Tau Protein](/proteins/tau)
[TREM2](/proteins/trem2)

Cell Types

[Endothelial Cells](/cell-types/endothelial-cells)
[Neurons](/entities/neurons)
[Microglia](/cell-types/microglia)
[Astrocytes](/cell-types/astrocytes)
[Pericytes](/cell-types/pericytes)

Treatments

[Focused Ultrasound Therapy](/therapeutics/focused-ultrasound-therapy)
[Nanoparticle Drug Delivery](/therapeutics/nanoparticle-drug-delivery)
[Immunotherapy](/therapeutics/immunotherapy)
[Blood-Brain Barrier Modulation](/therapeutics/blood-brain-barrier-modulation)
[Gene Therapy](/therapeutics/gene-therapy-neurodegeneration)

Implementation Roadmap

Estimated Timeline (4-6 years to IND)

| Phase | Duration | Key Milestones |
|-------|----------|----------------|
| Lead Optimization | 6-12 months | Screen brain-penetrant candidates, optimize PK/PD |
| Preclinical (IND-enabling) | 18-24 months | GLP toxicology, efficacy in AD/PD models, GMP manufacturing |
| IND-enabling studies | 12-18 months | GLP toxicology, CMC, regulatory meetings |
| Phase I | 12-18 months | Safety, dose-ranging in patients |

Estimated Cost

Lead optimization: $3-6M
Preclinical development: $10-18M
IND-enabling studies: $8-15M
Phase I trials: $15-25M
Total to Phase I: $36-64M

Academic Centers

University of Pennsylvania — Dr. John Trojanowski (AD therapeutics)

Stanford University — Dr. Marion Buckwalter (neuroinflammation)

UCLA — Dr. Varghese John (AD clinical trials)

University of Michigan — Dr. Henry Paulsen (biology)

Karolinska Institutet — Dr. Tomas M barek (mechanisms)

Potential Industry Partners

Biogen — Neuroscience pipeline

Roche — CNS portfolio

Merck — Neuroscience division

Takeda — Neuroscience acquisitions

AbbVie — CNS programs

Risk Assessment

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Brain penetration failure | Medium | High | Early PK/PD screening |
| Off-target effects | Low | Medium | Selectivity profiling |
| Clinical trial recruitment | Low | Medium | Multi-center design |

Regulatory Strategy

Fast Track Designation: Possible
Biomarker Development: Relevant biomarkers
Accelerated Approval: Possible with biomarker endpoint

References

Pardridge WM, "Blood-brain barrier drug delivery." NeuroRx (2021)

Abbott NJ, et al, "Structure and function of the blood-brain barrier." Neurobiol Dis (2010)

Hynynen K, et al, "Focused ultrasound-induced blood-brain barrier opening: a review of equipment and procedures." Phys Med Biol (2022)

Chowdhury EA, et al, "Advances in drug delivery to the central nervous system." Adv Drug Deliv Rev (2023)

Wu SY, et al, "Focused ultrasound enhances therapeutic antibody delivery in Alzheimer's disease mouse model." Adv Sci (2024)

Niu X, et al, "Ultrasound-mediated delivery of anti-amyloid beta antibodies across the blood-brain barrier." Mol Pharm (2023)

Karakatsani ME, et al, "Focused ultrasound for targeted delivery of neurotrophic factors in Parkinson's disease." J Parkinsons Dis (2024)

Pathway Diagram

The following diagram shows the key molecular relationships involving Focused Ultrasound-Enhanced Nanoparticle Delivery discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

ideas-delivery-focused-ultrasound-nanoparticle

▸Metadataorigin_type: v1_polymorphic_backfill

slug	ideas-delivery-focused-ultrasound-nanoparticle
kg_node_id	None
entity_type	idea
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5fde2a226923
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'ideas-delivery-focused-ultrasound-nanoparticle'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

55%

Debates

0

Incoming

11

Outgoing

18

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Focused Ultrasound-Enhanced Nanoparticle Delivery

Overview

Overview

Background

Mechanism of Action

Ultrasound-Induced Cavitation

Nanoparticle Design Considerations

Ultrasound Parameters

Safety Considerations

Applications in Neurodegenerative Disease

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Conditions

Combination Therapy Approaches

Future Directions

Clinical Translation

Current Status

Technical Challenges

Advantages Over Other Delivery Methods

Research Landscape

Key Research Groups

Major Publications

See Also

External Links

10-Dimension Scoring Rubric

Action Plan

Near-term (6-12 months)

Medium-term (1-2 years)

Key Experiments Needed

Potential Clinical Protocol

Academic Collaborators

Industry Partners

Next Steps

Short-Term (6-12 months)

Medium-Term (1-2 years)

Long-Term (2-3 years)

Key Experiments Needed

Rubric Score

Cross-Links

Diseases

Mechanisms

Proteins & Genes

Cell Types

Treatments

Implementation Roadmap

Estimated Timeline (4-6 years to IND)

Estimated Cost

Academic Centers

Potential Industry Partners

Risk Assessment

Regulatory Strategy

References

Pathway Diagram

💬 Discussion